Trial
NCT00300573
Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Incyte Corporation
Collaborators
—
Condition
HIV Infections
Intervention
Dexelvucitabine
Why stopped
Development program ended due to inability to pair with other cytidine analogs and higher risk of hyperlipasemia when not used with 3TC/FTC.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-08-23